ISM5059 / Insilico Medicine - LARVOL DELTA

ISM5059, a Novel Peripherally Restricted NLRP3 Inhibitor, Accelerates Healing of Diabetic Foot Ulcers (ADA 2026) - "These findings establish ISM5059 as an effective and selective peripheral NLRP3 inhibitor with robust efficacy and a promising safety margin for potential treatment of diabetic foot ulcers."

Metabolic Disorders • IL18 • IL1B • NLRP1 • NLRP3

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications (PRNewswire) - "In preclinical studies, ISM5059 has demonstrated high potency and selectivity, favorable safety profiles and excellent in vivo efficacy across animal disease models, supporting broad indication potential expanding into autoimmune and inflammatory diseases, metabolic diseases, cardiovascular diseases and ophthalmology diseases....Specifically, in the in vivo peritonitis model, ISM5059 demonstrated a robust, dose-dependent inhibition of Interleukin-1β (IL-1β), a potent pro-inflammatory cytokine as a master regulator of the inflammatory response."

New molecule • Preclinical • Cardiovascular • Immunology • Inflammation • Metabolic Disorders • Ophthalmology